Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-11-13
1993-11-23
Lee, Mary C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548110, 5483147, A61K 31415, C07D40300
Patent
active
052644499
ABSTRACT:
The present invention relates to new carbonyl 3R, 4R-ethyl-[(1-methyl-1H-imidazol-5-yl)methyl] -2-pyrrolidinone derivatives carrying a carboxyester-type lipophilic moiety on the pyrrolidinone nitrogen. More particularly, the present invention concerns new N-substituted carbonyl-3R,4R-ethyl-[(1-methyl-1H-imidazol-5-yl) methyl]-2-pyrrolidinone derivatives of the formula (I): ##STR1## wherein R is an optionally substituted hydrocarbon group, and pharmaceutically acceptable acid addition salts thereof.
The new compounds of the formula (I) are potent ocular hypotensives that are valuable antiglaucoma agents. They are also targeted for use in the treatment of so-called dry eye.
REFERENCES:
patent: 3470197 (1969-09-01), Van Dyke
J. Pharm. Sci., 62, 2021 (1973).
Allergan Inc.
Lee Mary C.
Whittenbaugh Robert C.
LandOfFree
N-substituted derivatives of 3R,4R-ethyl-[(1-methyl-1H-imidazol- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-substituted derivatives of 3R,4R-ethyl-[(1-methyl-1H-imidazol-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted derivatives of 3R,4R-ethyl-[(1-methyl-1H-imidazol- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1849147